EU funding application coordinated by Herantis Pharma has passed evaluation phase
(Thomson Reuters ONE) -
EU funding application coordinated by Herantis Pharma has passed evaluation
phase
Herantis Pharma Plc
Company release 8 Aug 2016 at 9:00 am
The European Commission has informed that the EU funding application TreatER,
coordinated by Herantis Pharma Plc ("Herantis"), has passed the evaluation phase
and is invited to start grant preparation. This does not yet constitute a formal
commitment for funding. The final decision by the European Commission depends on
the finalisation of grant preparation and the rest of the selection procedure.
The application concerns the company's planned first clinical study of CDNF in
Parkinson's disease. The grant application is titled "Clinical study in
Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein
for disease modification; 2) Validation of clinically tested device for
intracerebral drug delivery" and the requested grant from the Horizon 2020
Framework Programme amounts to approximately ?6 million.
Herantis expects to disclose the final result of the grant preparation by the
end of 2016. If the funding is granted Herantis expects it to clearly improve
the company's financial position.
Further information:
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246
About Parkinson's disease
Parkinson's disease is a slowly progressing neurodegenerative disease caused by
the death of dopaminergic neurons in the brains. Common first symptoms of the
disease include tremors, rigidity and slowness of movement. While the motor
symptoms can be treated with medication the disease progression cannot be
prevented, and the benefits of medication may be lost with disease progression
or side effects can become unmanageable. In addition, Parkinson's disease may
cause non-motor symptoms such as sleep problems, depression, and anxiety, which
are not alleviated by current Parkinson's drugs. Estimated 7 million people
worldwide have Parkinson's disease.
About CDNF
CDNF, or Cerebral Dopamine Neurotrophic Factor, is an endoplasmic reticulum
located and secreted protein with neuroprotective and neurorestorative
properties, patented worldwide by Herantis. Following a preclinical development
program, which has showed it as efficacious in several preclinical models of
Parkinson's disease (PD), Herantis is preparing for a first-in-human clinical
study of CDNF in the treatment of PD and has a preclinical development program
for the treatment of ALS.
In preclinical studies including chronic toxicology studies, CDNF administration
has been safe; CDNF has protected and regenerated midbrain dopamine-generating
cells suggesting a potential for disease modification of PD; it has also shown
efficacy in non-motor symptoms in PD. In an ALS disease model CDNF has
significantly increased survival and reduced symptoms. This suggests the
potential to address unmet clinical needs in both PD and ALS. CDNF is based on
research at the Institute of Biotechnology at the University of Helsinki, lead
by professor Mart Saarma.
About drug development in general
Drug development projects can usually be divided in two stages: The preclinical
stage, and the clinical stage involving human subjects. The clinical stage can
be further broken in three formal phases. Phase 1 clinical studies assess the
safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and
possible efficacy in the treatment of a particular disease is studied. Phase 3
studies finally aim to establish a statistical proof of safety and efficacy of
the drug candidate in typically hundreds or thousands of patients for market
approval. Drug development can take 10-15 years from the first preclinical
studies to market approval.
About Herantis Pharma Plc
Herantis Pharma Plc is a drug development company focused on early clinical
development of innovative drugs in unmet clinical needs. Our special emphasis is
in regenerative medicine where the company has two first-in-class assets based
on globally leading science in their fields: CDNF for neurodegenerative
diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer
associated lymphedema, with potential also in primary lymphedema. The shares of
Herantis are listed on the First North Finland marketplace run by Nasdaq
Helsinki stock exchange.
Distribution:
Nasdaq Helsinki
Main media
www.herantis.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Herantis Pharma Oyj via GlobeNewswire
[HUG#2033662]
Unternehmensinformation / Kurzprofil:
Datum: 08.08.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 487697
Anzahl Zeichen: 5695
contact information:
Town:
Helsinki
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"EU funding application coordinated by Herantis Pharma has passed evaluation phase"
steht unter der journalistisch-redaktionellen Verantwortung von
Herantis Pharma Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
